...A. Highlights: Organic sales growth exceeded 9% with double-digit growth from MedSurg and Neurotechnology businesses led by endoscopy, instruments and neuro cranial. 1. 2. Orthopaedics and Spine businesses delivered high single-digit growth, highlighting procedural recovery throughout qtr. 3. Internationally, posted mid-single-digit organic growth highlighted by double-digit organic growth in Europe and emerging markets. 4. Continued to have robust demand for capital products. 5. Had meaningful shipment delays due to ongoing product supply challenges, mostly affecting large capital businesses. 6. Adjusted EPS, $1.97. Reflected growth YoverY, despite ongoing impacts from inflationary pressures and significant premiums on inventory spot buys. a. 7. Expects these supply chain pressures to persist throughout year. They will moderate with less reliance on spot buys in 2H22. a. 8. Continued to invest in R&D at healthy rate of 7% of sales, demonstrating continued focus on new product pipelines....